The natural history of asymptomatic severe carotid artery stenosis  by Conrad, Mark F. et al.
From the Society for Vascular SurgeryFrom
Su
Auth
Pres
Su
Rep
En
H
m
The
to
m
0741
Cop
http
121The natural history of asymptomatic severe carotid
artery stenosis
Mark F. Conrad, MD, MMSc, Michael J. Michalczyk, BS, Arissa Opalacz, BS, Virendra I. Patel, MD, MPH,
Glenn M. LaMuraglia, MD, and Richard P. Cambria, MD, Boston, Mass
Background: Although level 1 evidence supports carotid endarterectomy (CEA) for stroke prevention in patients with
asymptomatic severe carotid artery stenosis (ASCAS; >70%), medical therapy alone has been promulgated by some as
equally effective. The goal of this study was to determine the natural history of medically treated patients with ASCAS.
Methods: Patients with ASCAS from 2005 to 2006 were identiﬁed in a health network database. Patients were included if
the initial therapeutic plan involved medical therapy alone (usually because of comorbidities or patient preference). Study
end points included: ipsilateral neurologic symptoms (INS) of transient ischemic attack and/or stroke, death, and INS
and/or death.
Results: There were 126 carotid arteries identiﬁed in 115 patients. Using standard duplex velocity criteria, 88 (70%) had
severe (70%-89%) and 38 (30%) had very severe stenoses (VSS; 90%-99%). The average age was 73.5 years, demographic
characteristics included: 66% hypertension, 64% coronary artery disease, 30% diabetes, 5% chronic kidney disease (CKD),
and 86% were taking a statin drug (28% had a low-density lipoprotein level <100 mg/dL). There were 31 patients (24.6%)
who developed INS during a mean follow-up of 27 months; most (23 of 31; 74%) occurred within 12 months of the
initial duplex ultrasound examination; 14 (45%) were strokes. The 5-year actuarial freedom from INS was 70.1 6 5%.
Multivariate predictors of INS included: VSS (hazard ratio [HR], 3.23; 95% conﬁdence interval [CI], 1.56-6.76; P [
.002), CKD (HR, 6.25; 95% CI, 2.05-19.2; P[ .001), and age (HR, 0.94; 95% CI, 0.91-0.98; P[ .001). There were 41
patients (33%) who underwent eventual carotid revascularization (32 CEA, nine stent); 23 of 41 (56%) were performed
for INS and 18 (44%) for plaque progression. Overall 5-year actuarial survival was 69.8%6 4.1%. Multivariate predictors
of death included: age (HR, 1.06; 95% CI, 1.03-1.1; P[ .0001), chronic obstructive pulmonary disease (HR, 1.92; 95%
CI, 1.08-3.41; P[ .03), and diabetes (HR, 5.08; 95% CI, 2.86-9.01; P < .0001). The 5-year actuarial freedom from INS
and/or death was 546 4.4%. Multivariate predictors of INS and/or death were: VSS (HR, 1.98; 95% CI, 1.22-3.23; P[
.006), CKD (HR, 5.46; 95% CI, 2.12-14.08; P[ .0004), and diabetes (HR, 2.6; 95% CI, 1.59-4.24; P[ .0001). Statin
use was not protective against INS or death in this cohort.
Conclusions:Medically managed patients with ASCAS develop INS early, especially in patients with VSS. Medical therapy
with aspirin and statins failed to control ASCAS, thus validating the role of CEA in these patients as promulgated in
multiple current treatment guidelines. (J Vasc Surg 2014;60:1218-26.)As detailed in virtually all currently available practice
guidelines, clinicians have traditionally relied on degree of
stenosis as the single most important lesion-centric factor
in recommending surgical intervention for asymptomatic
carotid stenosis.1 Early natural history studies emphasized
the ﬁnal degree of stenosis and the ﬁnding of progression
during observation to be signiﬁcantly correlated with stroke
risk referable to asymptomatic carotid stenosis.2 However,
such studies also emphasized the frequent concurrence of
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8of intervention for an asymptomatic carotid stenosis.
Although supported by available level 1 data3 and consensus
guideline recommendations,4,5 carotid endarterectomy
(CEA) and in particular, carotid artery stenting (CAS) for
asymptomatic carotid stenosis has been challenged in a series
of widely publicized review articles.6,7 Such challenges
generally follow two separate rationales. The ﬁrst of these
suggests that modern, optimal medical therapy affords an
equivalent or even superior degree of protection from stroke
referable to asymptomatic carotid stenosis, so as to obviate
the role of surgical intervention for such lesions irrespective
of degree of stenosis.6 In fact, there is only one prospective
study that substantiates this point of view8 and a consider-
able literature base refuting it.9-12 The second argument re-
lates to the fundamentals of carotid plaque pathology and
the pathogenesis of transient ischemic attack (TIA) and/
or stroke related to carotid bifurcation atherosclerosis. The
contention is that degree of stenosis is a poor surrogate for
the “at risk plaque” (ie, those with dynamic plaque events),
that are likely important in the pathogenesis of stroke-
related to carotid stenosis.
A number of carotid plaque characterization modalities
have been championed as being superior to degree of ste-
nosis in clinical decision-making. These include plaque
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imaging (MRI) studies,13 transcranial Doppler monitoring
of microembolic phenomenon related to (or as a conse-
quence of) carotid stenosis,14 and ﬁnally, a series of elegant
studies by Nicolaides et al, referable to high-resolution ul-
trasound plaque characterization.15,16 This list is hardly
comprehensive. However, the available data on carotid pla-
que pathology indicates that the correlation of any speciﬁc
plaque feature, be it plaque ulceration or intraplaque
hemorrhage (with symptomatic vs asymptomatic patients)
is, in fact, very poor.13 Stated differently, there is substan-
tial overlap in plaque features among symptomatic and
asymptomatic patients17; this implies of course that such
characteristics might not be particularly useful in clinical
decision-making. Perhaps degree of stenosis has remained
the principal variable used for clinical decision-making
because it is easily measured and therefore, ideal for longi-
tudinal observation in patients whose clinical and/or pla-
que features indicate that optimal medical therapy and
surveillance is the best management strategy. Reinforcing
the logic of this strategy is the abundant literature attesting
to the ominous implications of plaque progression during
observation.18-21
In this study, we address the natural history of asymp-
tomatic patients with a severe ($70% assessed using duplex
ultrasound [DUS] criteria) carotid stenosis from a hospital-
based cohort in whom, for a variety of reasons detailed
herein, the initial management strategy was that of medical
therapy alone and nonintervention for the carotid lesion.
The particular characteristics of our health care network’s
database allowed sequential observation and the inclusion
of important potentially confounding variables such as car-
diovascular risk factors and various medication usages.
METHODS
Patient identiﬁcation. Partners Healthcare maintains
a centralized clinical data registry of all inpatient and outpa-
tient encounters within the system. This database, the
Research Patient Data Registry, was searched for the inter-
national classiﬁcation of disease, ninth revision code for pa-
tients with asymptomatic carotid artery stenosis (433.10)
who underwent DUS scanning at the Massachusetts Gen-
eral Hospital in 2005 and 2006 (interval chosen in consid-
eration of follow-up duration). Details of the Research
Patient Data Registry search have been published in a
previous report.9 In brief, patients with a severe (70%-99%)
stenosis of at least one extracranial carotid artery were
identiﬁed and their medical records were reviewed to
determine their initial therapeutic plan. Patients who un-
derwent CEA or CAS within 6 months of this indexed
DUS study were excluded from the study as were those
who were considered symptomatic before the study. Each
carotid artery was considered a separate entity. There were
739 carotid arteries that met our deﬁnition of asymp-
tomatic severe extracranial carotid artery stenosis and had
appropriate clinical follow-up. Of these, 425 carotid ar-
teries underwent CEA or CAS based on the indexed study
and 166 carotid arteries were excluded because of thepresence of ipsilateral neurological symptoms within
6 months of the index DUS. An additional 22 carotid ar-
teries had a remote history of previous ipsilateral carotid
revascularization and were excluded such that the ﬁnal
cohort consisted of arteries with native asymptomatic severe
extracranial carotid artery stenosis. The Institutional Review
Board of the Massachusetts General Hospital approved this
clinical protocol and did not require patient consent.
Outcomes and deﬁnitions. Age was measured in years
for the multivariate analysis. Any patient with a history of
coronary artery disease (CAD) was placed in the CAD cate-
gory regardless of their revascularization status. Chronic
kidney disease (CKD) was based on glomerular ﬁltration
rate (GFR) using the standard K/DOQI classiﬁcation sys-
tem in which patients with CKD 4 (GFR, 15-29 mL/
min/1.73 m2) and CKD 5 (GFR, <15 mL/min/
1.75 m2) were considered to have severe disease.22 Pa-
tients were placed in the high risk for intervention category
based on the medical judgement of the treating physician.
Asymptomatic status. Asymptomatic patients had no
history of ipsilateral neurologic events including TIA,
stroke, and amaurosis fugax within the 6 months before
the index DUS. This time interval was chosen based on
the deﬁnition used by the Asymptomatic Carotid Surgery
Trial (ACST) collaborative group and is further supported
by the DEFINE group, who concluded that patients who
experienced neurologic events >6 months previously
should be considered asymptomatic because the risk of
recurrent stroke decreases over time.23,24
Severe carotid stenosis. The severe stenosis category
corresponded to a 70% to 99% diameter reduction of the in-
ternal carotid artery (ICA). Our vascular laboratory uses the
following criteria to differentiate severe and very severe ste-
noses (VSS). In the ICA, a peak systolic velocity >250 cm/
sec, end diastolic velocity of <135 cm/sec, and an ICA/
common carotid artery ratio >4.0 deﬁne severe stenosis
and very severe stenosis (90%-99%) of the ICA is deﬁned
by a peak systolic velocity>250 cm/sec, end diastolic veloc-
ity >135 cm/sec, and ICA/common carotid artery ratio
>5.0. These values were initially based on a comparative
study of carotid plaque specimens25 by our neurologists.
The primary end points for the study were death,
development of ipsilateral neurologic symptoms (INS;
TIA and/or stroke) and a composite INS and/or death
rate. Survival was determined by a review of the medical re-
cord and Social Security Death Index when necessary.
Other end points were deﬁned as follows.
Development of INS. Patients who experienced an
episode of stroke, TIA, or amaurosis fugax referable to
the ipsilateral carotid artery after the date of the index
DUS were considered to have become symptomatic. All
patients who developed stroke symptoms were evaluated
by a neurologist and anatomic defects were conﬁrmed using
computed tomography or MRI imaging of the brain. Pa-
tients whose symptoms lasted <24 hours and had no stroke
on brain imaging were considered to have had a TIA.
Operative intervention. All ipsilateral procedures per-
formed on the ICA were documented including CEA and
Table I. Demographic and clinical data stratiﬁed
according to stenosis severity
Variable
Entire
cohort
(N ¼ 126)
Severe:
70%-89%
(n ¼ 88)
VSS:
90%-99%
(n ¼ 38) P
Mean age, years 73.5 72.9 73.7 .71
Male sex 64 (51) 50 (57) 14 (37) .03
White race 120 (95) 85 (97) 35 (92) .28
CAD 81 (64) 52 (59) 29 (76) .06
Hypertension 96 (76) 66 (75) 30 (79) .63
CHF 39 (31) 26 (30) 13 (34) .60
CKD4/5 6 (5) 3 (3) 3 (8) .28
COPD 38 (30) 21 (24) 17 (45) .02
Diabetes 38 (30) 29 (33) 9 (24) .30
PVD 73 (58) 50 (57) 23 (61) .70
High risk 43 (34) 27 (31) 16 (42) .21
CAD, Coronary artery disease; CHF, congestive heart failure; CKD, chronic
kidney disease; COPD, chronic obstructive pulmonary disease; PVD,
peripheral vascular disease; VSS, very severe stenoses.
Except for mean age, data are presented as number (%).
Table II. Medications and laboratory values stratiﬁed
according to stenosis severity
Variable
Entire
cohort
(N ¼ 126)
Severe:
70%-89%
(n ¼ 88)
VSS:
90%-99%
(n ¼ 38) P
Statins 108 (86) 75 (85) 33 (87) .81
HD statins 18 (14) 12 (14) 6 (16) .75
Aspirin 112 (89) 76 (86) 36 (95) .17
Aspirin with statins 100 (79) 68 (77) 32 (84) .38
ACE/ARB 75 (60) 55 (63) 20 (53) .28
b-blocker 96 (76) 63 (72) 33 (87) .07
Clopidogrel 43 (34) 25 (28) 18 (47) .04
Warfarin 30 (24) 23 (26) 7 (18) .35
LDL <100 mg/dL 35 (28) 16 (18) 19 (50) .0003
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
HD, high dose; LDL, low-density lipoprotein; VSS, very severe stenoses.
Data are presented as number (%).
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were at the discretion of the individual physician.
Statistical analysis. Categorical demographic and
clinical data are presented as the percentage prevalence in
the study population. Continuous data are presented as
mean 6 standard deviation. Univariate analysis was per-
formed using two-tailed t-tests for continuous variables
and c2 analysis for categorical data. All long-term out-
comes with variable follow-up including survival and
freedom from INS were determined using Kaplan-Meier
analysis. Cox proportional hazards models were created
to identify multivariate predictors of death and INS
development. A P < .05 was considered statistically sig-
niﬁcant. Statistical analysis was performed using SAS 9.2
software (SAS Institute Inc, Cary, NC).
RESULTS
There were 126 carotid arteries identiﬁed in 115 pa-
tients. Carotid arteries were stratiﬁed according to severity
of stenosis: 88 (70%) had severe (70%-89%) and 38 (30%)
had VSS (90%-99%). The average age at initial duplex was
73.5 (range, 44-91) years, comorbidities included: 76% hy-
pertension, 64% CAD, 30% diabetes, and 5% severe CKD
(grade, 4-5). Demographic characteristics stratiﬁed accord-
ing to stenosis severity are summarized in Table I. The
groups were similar except for sex and chronic obstructive
pulmonary disease (COPD); the VSS cohort had a greater
percentage of female patients and patients with COPD.
The reason patients were treated with medical therapy
alone was that they were classiﬁed as high risk for interven-
tion in 43 (34%) patients, physician recommendation in 69
(55%) patients, and 14 patients (11%) refused an initial rec-
ommended intervention. The recommendation of medical
therapy alone was made by a vascular surgeon in 41 pa-
tients (33%), a cardiologist in 57 patients (45%), and a
neurologist in the remaining 28 patients (22%). Most pa-
tients in the cohort (86%) were taking a statin and 15%were using the maximum dose. In addition, in 35 patients
(28%) all low-density lipoprotein (LDL) levels evaluated
during the study period were <100 mg/dL. Most patients
(89%) were taking aspirin and 100 (79%) were taking
aspirin and statin dual therapy. Additional antiplatelet ther-
apy with clopidogrel was used in 43 patients (34%) and 30
patients (24%) were taking warfarin. Medications and labo-
ratory values stratiﬁed according to stenosis severity are
presented in Table II. The groups were similar except for
clopidogrel use and LDL level <100 mg/dL; both of
which were signiﬁcantly greater in the very severe cohort.
The average follow-up was 63 (range, 2-90) months
and the median was 71 months. There were 31 (25% of ca-
rotid arteries) patients who developed INS during the
follow-up period and most 23 of 31 (74%) occurred within
12 months of the initial DUS; 14 (45%) were strokes and
17 (55%) were either retinal or hemispheric events. The
5-year actuarial freedom from INS was 70.1 6 5%
(Fig 1). Freedom from INS was then stratiﬁed according
to degree of stenosis and was signiﬁcantly better in the se-
vere cohort (80% severe, 45% VSS; P ¼ .003; Fig 1). Statin
use did not prevent INS in this cohort and the 5-year
freedom from INS was 70% in patients who were and
were not takin a statin (P¼ .98; Fig 2). Multivariate predic-
tors of INS included: VSS (hazard ratio [HR], 3.23; 95%
conﬁdence interval [CI], 1.56-6.76; P ¼ .002), CKD 4/5
(HR, 6.25; 95% CI, 2.05-19.2; P ¼ .001), and age (per
year; HR, 0.94; 95% CI, 0.91-0.98; P ¼ .001).
There were 41 patients (33%) who underwent eventual
carotid revascularization (32 CEA, 9 stent). The average
time from initial DUS to revascularization was 16 months
(range, 4-73 months). Most procedures (n ¼ 23; 56%)
were performed for INS but 18 (44%) had plaque progres-
sion as the indication for intervention. There were no peri-
operative strokes or deaths in the patients who underwent
revascularization. There were eight patients who had INS
but did not undergo revascularization. Of these, two had
carotid occlusions, one died from hemorrhagic conversion
of a large infarct, and the remaining ﬁve were so debilitated
Fig 1. Kaplan Meier curve of freedom from ipsilateral neurologic
symptoms (INS) in the entire cohort and stratiﬁed according to
lesion severity. The P value for the difference between severe and
very severe stenosis was .003.
Months
0 12 24 36 48 60
Entire cohort
At risk, No. 126 92 71 51 38 27
SE, % 3.3 3.3 3.8 4.1 4.6 5
Severe
At risk, No. 88 67 48 36 25 16
SE, % 1.1 3.8 4.3 4.3 4.8 4.8
Very severe
At risk, No. 38 18 12 9 5 5
SE, % 2.6 8.1 9 9 11 11
SE, Standard error.
Fig 2. Kaplan-Meier curve of ipsilateral neurologic symptoms
(INS) stratiﬁed according to statin use. The difference was not
signiﬁcant (P ¼ .98).
Months
0 12 24 36 48 60
No statin
At risk, No. 18 10 6 5 3 2
SE, % 5.4 9.6 9.6 13.6 13.6 13.6
Statin
At risk, No. 108 75 54 42 27 19
SE, % 1.3 3.9 4.2 4.3 5.2 5.2
SE, Standard error.
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during follow-up). There were 41 patients (33%) who died
without revascularization and the remaining 44 (34%) of
patients are alive. The 5-year actuarial survival was
69.8 6 4.1% (Fig 3). Degree of stenosis did not affect sur-
vival (67% severe, 68% VSS; P ¼ .43). Multivariate predic-
tors of death included: age (per year; HR, 1.06; 95% CI,
1.03-1.1; P ¼ .0001), COPD (HR, 1.92; 95% CI, 1.08-
3.41; P ¼ .03), diabetes (HR, 5.08; 95% CI, 2.86-9.01;
P < .0001), and high risk for surgery (HR, 2.51; 95%
CI, 1.44-4.41; P ¼ .001).
The 5-year actuarial freedom from the composite end
point of INS and/or death was 54 6 4.4% (Fig 4). Multi-
variate predictors of INS and/or death were: VSS (HR,
1.98; 95% CI, 1.22-3.23; P ¼ .006), CKD 4/5 (HR,
5.46; 95% CI, 2.12-14.08; P ¼ .0004), and diabetes
(HR, 2.6; 95% CI, 1.59-4.24; P ¼ .0001). Statin use was
again not protective from INS or death in this cohort.
DISCUSSION
Although initially assessments were made with catheter-
based arteriography, the role of DUS in assessment of
carotid stenosis is ﬁrmly established. Asymptomatic carotidbifurcation stenosis is a potentially signiﬁcant public health
problem. Epidemiologic studies indicate that 5% to 6% of
the >65 years of age population will harbor an asymptom-
atic and potentially surgically signiﬁcant carotid stenosis.26
Stroke itself remains an important public health problem
as the third leading cause of death in the United States26
and, 10% to 20% of ischemic strokes can be attributed to
an ipsilateral, typically high-grade carotid stenosis.27 The
literature linking the degree of stenosis of the ICA and
risk of ipsilateral stroke dates to the natural history studies
published by Chambers and Norris in the 1980s.2 These in-
vestigators demonstrated a signiﬁcant correlation of stroke
risk with a>70% ipsilateral carotid artery stenosis. However,
in these studies, patients with signiﬁcant carotid stenosis also
had substantial rates of overall cardiovascular-related death
such that the natural history data were hardly a resounding
endorsement of intervention for asymptomatic carotid ste-
nosis. Randomized prospective trials such as the Asymptom-
atic Carotid Artery Stenosis (ACAS) study published in
1995 and themore recently updated ACST indicated a quite
similar annual stroke risk in the 2% range for patients treated
with medical therapy as opposed to those randomized to
CEA.23,28 Ten-year follow-up data in the ACST trial
demonstrated a sustained beneﬁt for endarterectomy over
optimal medical therapy.29 It is important to emphasize
that in this trial some 80% of patients were taking optimal
medical therapy (aspirin with statin agents) in the later years
Fig 3. Kaplan-Meier curve of survival of the entire cohort.
Months
0 12 24 36 48 60
No statin
At risk, No. 126 124 117 108 96 88
SE, % 1.1 1.1 2.3 3.1 3.8 4.1
SE, Standard error.
Fig 4. Kaplan Meier curve of ipsilateral neurologic symptoms
(INS)-free survival.
Months
0 12 24 36 48 60
No statin
At risk, No. 126 107 97 87 75 68
SE, % 1.1 3.2 3.7 4.1 4.4 4.4
SE, Standard error.
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protective effect of endarterectomy was more pronounced
in those not taking appropriate lipid-lowering therapy (the
10-year advantage of endarterectomy over medical therapy
in the prevention of stroke was 5.8% in patients taking a
statin and 6.2% in those who were not); the protective effect
of endarterectomy over optimal medical therapy was statis-
tically signiﬁcant (P ¼ .002).29 This is of course relevant
because clinicians in the modern era have typically used
data from the ACST to counsel patients about the stroke
risk of asymptomatic high-grade carotid stenosis.
Our data reported herein indicate that in a small
hospital-based cohort harboring asymptomatic high-grade
carotid stenosis and wherein at least 80% of the patients
had what most would consider optimal medical therapy,
the neurologic event (ipsilateral TIA and/or stroke) was
a bit higher than 5% per year out to 5 years of follow-up
from the initial duplex scan. Overall, 25% of the cohort
developed such INS and most of these (71%) occurred in
the ﬁrst 12 months of study. Similar to the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)10
and Asymptomatic Carotid Stenosis and Risk of Stroke
(ACSRS)15 studies, neurologic events segregate into TIA
and stroke in approximately a 50:50 distribution. These
data of course indicate that a strategy of waiting for a
TIA to intervene on an asymptomatic severe carotid steno-
sis is unsafe; a revelation that is not new to physicians who
treat carotid disease. The de novo stroke rate in the current
series was approximately 2.5% per year, which is similar to
the ACST trial and the follow-up NASCET studies of
asymptomatic carotid stenosis contralateral to the index ca-
rotid for which patient entry was developed.10,29 The lattervaluable study was notable not only for following up on
stroke risk in patients who harbored asymptomatic carotid
stenosis but also that the exact pathogenesis of the stroke
could be ascertained. The NASCET investigators indicated
that for patients with $70% NASCET criteria asymptom-
atic stenosis, the annual risk of carotid-related stroke was
approximately 2% per year.10 These data are accordingly
concordant with those reported herein. Importantly, our
study, unlike some others, indicated that the risk of ipsilat-
eral neurologic events was signiﬁcantly greater in those
with the highest (90%-99%) stenosis. As reported herein,
the annual event rate in such patients was >10% per year
equating to an annual de novo stroke risk of 5% per year.
In the NASCET study, annual stroke risk for those with
such critical (90%-99%) stenosis was also quoted at 4%
per year.10
The largest recently completed prospective study of
stroke risk related to asymptomatic carotid stenosis was
the ACSRS study conducted in Europe, the results of
which were ﬁrst published in 2005.15 In this study, some
1000 asymptomatic patients who harbored varying degrees
of carotid stenosis were prospectively followed without
intervention for a mean follow-up period of 37 months at
the time of the 2005 publication.15 Although there was
an attempt to stratify the implications of assessing carotid
stenosis by the ACST vs the NASCET method, there
were some 900 patients followed prospectively who had a
degree of carotid stenosis (ie, >70% diameter reduction)
wherein recommendation for CEA would have been justi-
ﬁed by current practice guidelines. In such patients, the
overall ipsilateral neurologic event rate was 10% at 3 years
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 5 Conrad et al 1223and again there was approximately a 50:50 distribution of
TIA and stroke.15 Furthermore, similar to the present
study, the highest risk was clustered among those with
truly critical 90% to 99% stenosis. These investigators indi-
cated that certain clinical features such as a previous contra-
lateral TIA or the presence of chronic renal insufﬁciency
(similar to our own data) increased overall stroke risk. In
the follow-up study, these investigators demonstrated
that a combination of clinical and lesion-centric duplex
criteria could segregate patients into high or low risk of
ipsilateral stroke. Nonetheless, the most recently presented
data from the ACSRS investigators indicates that the two
strongest correlates of stroke risk in this trial were the ﬁnal
degree of stenosis and the observation of progression dur-
ing observation.30
Contrary to the data reported herein and the concor-
dant literature as reviewed herein, certain prospective clin-
ical trials had detailed substantially lower neurologic event
rates in medically treated patients with carotid stenosis. In
the Secondary Manifestation of Arterial Disease Trial,
nearly 300 patients with asymptomatic carotid stenosis of
$50% were followed with optimal medical therapy for
6 years. These authors reported an annual de novo stroke
risk of 0.5% even for patients harboring 70% to 99% steno-
sis.8 This is consistent with an earlier report from this study
group, which is frequently quoted to substantiate the low
risk of stroke in patients with asymptomatic carotid stenosis
with use of optimal medical therapy.31 Although the expla-
nation for the discrepancy between this prospective trial
and the extant natural history literature as reviewed herein
is unknown, it might relate to the close supervision and
optimization of medical therapy in patients in such
prospective clinical trials. An example would be the 3164
patients in the Reduction of Atherothrombosis for
Continued Health (REACH) registry with severe (>70%)
carotid stenosis wherein a twofold increase in cerebrovascu-
lar events was recorded when compared with the 30,329
patients who were free of carotid stenosis (5.73% vs
2.55%). Because this is a registry of 5000 hospitals in 44
countries, it is more likely to represent real world medical
management than a prospective trial; 70% of patients in
REACH were taking a statin.32
Our data should not be interpreted as a negative
comment on the worth of additional diagnostic modalities
to “risk stratify” patients with asymptomatic carotid steno-
sis.33 For example, the elegant parallel studies related to ca-
rotid plaque pathology published by the ACSRS
investigators show impressive correlation with certain
ultrasound-characterized plaque features and the risk of
ipsilateral stroke.34 In addition, other modalities such as
transcranial Doppler detection of asymptomatic microem-
bolic phenomenon show a strong correlation with degree
of stenosis and such asymptomatic detected microem-
boli.14 Although useful in research considerations, it would
appear that expensive axial imaging studies such as MRI
plaque characterization are impractical to suggest as
broadly applied plaque characterization modalities. In addi-
tion to the absolute degree of stenosis, the practice ofsequential surveillance of patients with moderate or border-
line severe carotid stenosis seems ﬁrmly endorsed by an
abundant literature testifying to the signiﬁcant incidence
and the ominous neurologic implications of plaque pro-
gression. In fact, there is available literature indirectly or
directly suggesting that even optimal medical therapy will
often fail to control carotid plaque progression.9 In a pre-
vious study on the inﬂuence of medical therapy on patients
with asymptomatic moderate carotid stenosis who, by all
guidelines, are managed with optimal medical therapy
and serial follow-up, we found plaque progression (ie,
from moderate to severe stenosis) or INS advent to occur
in nearly 50% of such patients if followed for 5 years.
Furthermore, there was no difference in such plaque pro-
gression irrespective of whether appropriate LDL targets
were achieved; >80% of all patients were taking optimal
medical therapy.9 Concordant with these data are data
from the ACSRS study and single-center reports that
show plaque progression despite use of statin therapy and
the presence of said progression was strongly correlated
with the development of stroke.18,21,30,35,36 In our study,
even though all patients had a threshold stenosis assessed
using duplex scan, a variety of clinical features including
high surgical risk in at least a third occasioned an initial
management strategy of medical therapy alone. A third of
the patients in this cohort subsequently underwent a ca-
rotid revascularization at an average interval of 16 months
after their index duplex scan. Among these patients,
approximately half of these interventions were for the
development of INS and the remainder underwent surgery
or stenting because of observed plaque progression.
Our data should not be interpreted as a blanket
endorsement of intervention for severe asymptomatic ca-
rotid stenosis. Clinicians should broadly appreciate the
fact that there are lesion-centric and patient-centric features
equally important in clinical decision-making. At least one
clinical feature, CKD 4/5, presents a conﬂict for decision-
making. Both the present study and the ACSRS study indi-
cate CKD signiﬁcantly increases stroke risk in medically
managed patients with severe asymptomatic carotid dis-
ease; yet, its independent limitations on survival are well
recognized.37,38 Obviously no blanket recommendation
can be made either in favor or against intervention in
such patients. The Society for Vascular Surgery guidelines
indicate that on a clinical basis a patient should have a min-
imum of a 3-year projected life expectancy to derive appro-
priate beneﬁt from an intervention for asymptomatic
carotid stenosis.5 It is of course logical that any carotid
intervention for asymptomatic disease should only be
applied in those whose longevity is such that they can
derive beneﬁt from such intervention. We and others
have recently focused on the late outcomes of patients un-
dergoing CEA for asymptomatic disease. We found that
readily apparent clinical features have an additive and
signiﬁcantly predictive effect on patient longevity. In a
cohort of 2004 CEAs performed over a 16-year period
we identiﬁed advanced age, CAD, COPD, diabetes,
CKD, and lack of statin therapy as negative predictors of
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predict long-term survival after CEA. The lowest-risk pa-
tients had a 5-year survival of 93% and survival in the
highest-risk group was 34%.37 Similarly, Wallaert et al pre-
sented late outcomes in a cohort of patients prospectively
followed in the New England Vascular Quality Initiative.
These investigators reported a 5-year life expectancy of
82% in a cohort of 4114 patients who underwent surgery
for asymptomatic carotid stenosis. They identiﬁed risk fac-
tors similar to those in our study with the addition of
contralateral CEA, and reported an actuarial survival of
96% in the low-risk and 51% in the high-risk cohort.38
The limitations of our retrospective study include the
fact that this was a health care system-based cohort;
although these were not necessarily hospitalized patients,
this cohort might represent one whose risk features are
not equivalent to those in the average outpatient setting.
Indeed, the risk factor proﬁle in our present study and its
signiﬁcant effect on mortality is quite clear; furthermore,
certain risk factors that are potentially important in neuro-
logic symptom advent such as active cigarette smoking
could not be reliably tracked in our database and are
accordingly omitted herein. The data herein do refute the
contention that the risk of stroke referable to high-grade
asymptomatic carotid stenosis is no greater than the risk
of CEA. Data, for example, from the Carotid Revasculari-
zation Endarterectomy vs Stenting Trial (CREST) indicate
that CEA when performed by vascular surgeons was
accompanied by a 1% risk of periprocedural stroke and
death in symptomatic and asymptomatic patients.39 In
our own recently published cohort of 3014 patients who
underwent endarterectomy over a 15-year interval and
obviously representing a broader spectrum of patients
than represented in randomized trials, perioperative stroke
and death occurred in 2.2% of patients.40 There is an abun-
dant literature testifying to the current safety and efﬁcacy of
CEA, which, is of course an important variable in clinical
decision-making.
CONCLUSIONS
Although an imperfect surrogate, degree of stenosis re-
mains a reliable predictor in incremental fashion of neuro-
logic events in patients with asymptomatic carotid stenosis.
The argument that medical management alone is the new
standard of care for asymptomatic severe carotid stenosis
is ﬂawed in that it relies on studies that include a dispropor-
tionate number of patients with moderate (50%-69%) ste-
nosis. The data herein conﬁrm that medically managed
patients with severe (>70%) carotid stenosis develop INS
early and support the validated evidence base for CEA in
the prevention of stroke in appropriate patients.
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your cohort reached a target low-density lipoprotein (LDL) level.
Many proponents of medical management would comment that
perhaps these patients were not therefore optimally medically
managed. Do you think that the lack of statin effect is because the
LDL targets were not reached?Do you think achieving these targets
is a realistic goal in clinical studies and in real world experience?
Dr Mark F. Conrad. I think the LDL target is a very impor-
tant part of medical management, but I also think that the concept
of optimal medical management has become the Holy Grail of ca-
rotid disease. It seems like it can never be adequately accomplished
in normal practice. I think as we move forward with asymptomatic
carotid studies, we are going to see that patients in the medical
arms, with close patient monitoring and frequent medication and
laboratory checks, are going to do well. But in a real world expe-
rience, I think it is very difﬁcult to make sure that they are taking
their statin every day and that their LDL levels are where they need
to be.You have to also remember this cohort is from 2005 and
2006, so we focused more on LDL levels later in the study and
that could explain the low number of patients with adequate levels.
But, yes, if everybody had taken their statin every day and their
LDL levels were <100 mg/dL, the results might have been
different.
Dr Ali AbuRahma (Charleston, WVa). I have a few questions
for Dr Conrad:
(1) How many of your patients progressed to total carotid
occlusion and how many of these were symptomatic at
the time of occlusion?
(2) How could you distinguish between 70% to 90% steno-
sis vs 90% to 99% stenosis? In our laboratory, we have
difﬁculty distinguishing between these two categories
of stenoses using duplex ultrasound.
(3) Your conclusion differs somewhat from the North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) conclusion in that the NASCET patients
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with 70% to 90% stenosis. I would appreciate your
response to these questions. Thank you.
Dr Conrad. Actually, very few went on to develop occlusions.
We only had 3 occlusions and they were all symptomatic at the
time.
With regard to our division between severe and very severe, it
has changed over time, but we currently use a peak systolic velocity
of 250 as the threshold for severe category. And a diastolic velocity of
125or a ratio of>4would put the patient into the 90% to 99% range.
With regard to the asymptomatic patients from NASCET, the
event rate for patients with 75% to 99% stenosis was 18.5% at
5 years.
Dr Bruce Perler (Baltimore, Md). I just have a question to
allow you to speculate a bit. Based on your data, how comfortable
would you be randomizing an asymptomatic patient with a >90%
stenosis, for example, in the Carotid Revascularization Endarterec-
tomy vs Stenting Trial (CREST) II? Could you comment on any
ethical concerns of randomizing such a patient based on what
you have just presented.
Dr Conrad. I think that is a great philosophical question. I
think that everybody has to decide for themselves if they think
that this is a surgery that helps asymptomatic people. I think it
does and we are a very aggressive group when it comes to treating
asymptomatic carotid disease. I have to say that I am not a fan of
randomizing anybody to medical therapy when it comes to severe
stenosis but would do so for a trial.
Dr Wesley Moore (Los Angeles, Calif). I really enjoyed your
presentation and I was struck by the high event rate that you re-
ported in your asymptomatic patient population. As I recall, it was
29% in 5 years. In the data from the Asymptomatic Carotid Artery
Stenosis (ACAS) trial, whichwas controlled by contrast angiography
and duplex ultrasound, the event rate at the end of 5 years for the
medically treated group was 11%, or approximately 2.2% per year.
Now, the argument that Anne Abbott and others have put
forth is that their observation suggests that the annual event rate
for patients with asymptomatic, hemodynamically signiﬁcant carotid
stenosis might now be down to approximately 1% per year. If that is
the case, then we would have a very difﬁcult time showing a beneﬁt
of intervention over best medical management. I think your obser-
vation that Dr Abbott and others might be looking at in patients
with lesser stenosis than we would consider for intervention is fair.
I do want to put in a pitch for participation in CREST II. We are
under the gun right now from a lot of sources reporting we are per-
forming needless surgeries based on reports by Abbott and others.
We need to prove the efﬁcacy of intervention plus contemporary
best medical management vs best medical management alone.
CREST II is our last best chance to accomplish this objective.
As far as making sure that we have high-grade stenosis patients
in CREST II, the threshold for stenosis entry will be a peak systolicvelocity of 300. I think that will probably answer the question as to
whether we are including the high-grade stenosis group.
But getting back to your event rate of 29% in 5 years, which is
much greater than anyone has reported to date, I am wondering if
there is something different about the selection of your patient
cohort vs that which was seen in ACAS? You might have identiﬁed
the Holy Grail in identifying the high-risk group. Please share that
information with us.
Dr Conrad. I appreciate your comments regarding CREST
II. It’s funny, when you present low stroke rates after carotid end-
arterectomy (CEA), the cardiologists say you are underreporting
them. Now, we are presenting higher stroke rates with medical
management and the concern is that we are overreporting them.
I think this is a sicker group of patients than in ACAS because
many were not considered candidates for endarterectomy. We did
not go back and examine plaque morphology to predict symptom
development. We relied on the degree of stenosis for that.
Dr A. Ross Naylor (Bushby, United Kingdom). As Wes
Moore has just said, the key issue here is that you seem to have
identiﬁed a cohort who are behaving like symptomatic patients.
To my knowledge, no natural history or randomized study has
ever shown symptoms at such a high rate at 12 months, as you
are currently reporting. Accordingly, I think it would be wrong
to use this study to conclude that there is no need for reviewing
practice in asymptomatic patients.
I would also point out that there is a lot of guff being promul-
gated on the inclusion of moderate stenoses in the debate on
contemporary natural history studies. For example, if you compare
the ﬁrst 5 years of ACAS (1995), and the ﬁrst 5 years of Asymp-
tomatic Carotid Surgery Trial (ACST; 2004), and the second
5 years of ACST (2010), there have been sustained reductions in
the 5-year risk of any stroke and ipsilateral stroke across all three
time periods. So there is something out of kilter with your study
results compared with everything else that is going on.
Dr Patrick Geraghty (St. Louis, Mo). The 10-year follow-up
data from the ACST trial actually supported an aggressive
approach to CEA, in my opinion, because they analyzed patients
who were taking lipid-lowering therapy as a separate subset.
Lipid-lowering therapy lowered event rates in the immediate and
deferred arms, but patients still received more beneﬁt from the im-
mediate CEA. So I congratulate you for investigating this. I’ll let
Dr Cambria address your event rates; my point is that I do not
believe we should abandon CEA for asymptomatic disease quite
yet.
Dr Richard Cambria (Boston, Mass). I just wanted to correct
Dr Naylor. In the NASCET natural history study of asymptomatic
carotid lesions, for those with a surgically signiﬁcant lesion of
$60% according to the NASCET criteria, the overall annualized
risk was 2% per year. In those with 75% to 99% stenosis it was
4% per year, which approximates the data shown here.
